(3R)-2-(2-methoxyphenyl)-5-(4-nitrophenyl)-3-phenyl-3,4-dihydropyrazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (3R)-2-(2-methoxyphenyl)-5-(4-nitrophenyl)-3-phenyl-3,4-dihydropyrazole
• 化学式: C22H19N3O3
• 分子量: 373.4
• InChiKey: OFUOEGQNHUFNKF-OAQYLSRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  70.6
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS D'ACCUMULATION DE LIPIDES DE MYOCYTES ET D'INSULINORÉSISTANCE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST

  公开号：WO2017019772A1

  公开（公告）日：2017-02-02

  Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.

  已开发了用于降低血糖和/或增加受试者胰岛素信号的配方和方法。这些配方包括SBI-477和基于SBI-477的化合物，即SBI-477类似物（统称为SBI-477化合物）和/或Mondo家族抑制剂，以有效量抑制细胞内脂质积累和/或增加细胞葡萄糖摄取，与未施用该组合物的对照受试者相比。还公开了用于减少细胞内脂质积累和/或增加受试者葡萄糖摄取的方法。该方法包括向受试者施用足够量的SBI-477化合物和/或Mondo家族抑制剂，以减少受试者细胞内脂质积累和/或增加葡萄糖摄取。还公开了用于治疗一种或多种Myc驱动的癌症的方法，包括神经母细胞瘤、肺鳞状细胞癌/肺腺癌、肝细胞癌、结肠腺癌、急性髓系白血病和乳腺浸润性癌。